Hepatitis C virus (HCV) infection is one of the major concerns in public health. Currently, optimal antiviral therapy with pegylated interferon-alpha plus ribavirin, cures ~50% of patients infected with HCV genotype 1 and ~80% of patients infected with HCV genotypes 2 and 3. One of the difficulties regarding our understanding on treatment resistance is related to the nature of current antiviral agents. Both interferon and ribavirin have long been known for their broad-spectrum antiviral activity by creating a non-specific antiviral status rather than the direct interaction with viruses. Consequently, no explicit targets on HCV genome have been documented. Studies on drug resistance with these agents have generated very controversial data through conventional approaches that frequently focus on short domains of the HCV rather than the entire viral genome. Using a novel long RT-PCR and cloning technology and well- characterized serum samples from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial (HALT-C), we propose a viral sequencing project through which viral mechanisms for the resistance to antiviral therapy will be exhaustively examined at multiple levels. HYPOTHESIS: HCV resistance to antiviral therapy is associated with region-dependent mutations of viral quasispecies at either single variants or the population level.
Aim 1 : To explore genetic signatures at both HCV isolate and quasispecies levels in null responders infected with HCV genotype 1a. The full-length HCV quasispecies profiles at the baseline will be generated from patients with either null or sustained virological responses (SVR), followed by comparative analyses to identify potential genetic signatures that are associated with the treatment resistance.
Aim 2 : To demonstrate if there are distinct quasispecies structures of HCV genotype 2 in terms of the high response rate to the antiviral therapy. The full-length HCV quasispecies profiles will be generated from twenty SVRs with HCV genotype 2a, followed by comparative analyses with those derived from HCV genotype 1a.
Aim 3 : To characterize mutational patterns associated with HCV re-emergence in patients with relapse after initial response to antiviral therapy. The relapse indicates the survival of HCV from a putative population bottleneck formed under antiviral therapy. How does HCV respond to such ?in vivo? population bottlenecks? This issue will be addressed through a sequential comparative analysis of full-length HCV quasispecies profiles. Data from these studies will have immediate applications for rational design of future HCV antiviral therapy in which PegIFN-? and ribavirin are still the core components. Project Narrative Hepatitis C virus infection is one of the major concerns in public health and current antiviral therapy has very differential success within and among HCV genotypes. We will examine viral determinants responsible for the treatment resistance through the application of novel technology. This may help to design more effective antiviral therapy to chronic HCV infection.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-9 (J1))
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Saint Louis University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Wang, Weihua; Ren, Yi; Lu, Yang et al. (2017) Template-dependent multiple displacement amplification for profiling human circulating RNA. Biotechniques 63:21-27
Ren, Yi; Wang, Weihua; Zhang, Xiaoan et al. (2016) Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. J Gen Virol 97:334-43
Lin, Jianguo; Wang, Weihua; Xu, Yanjuan et al. (2015) Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy. J Med Virol 87:821-8
Wang, Weihua; Zhang, Xiaoan; Xu, Yanjuan et al. (2014) High-resolution quantification of hepatitis C virus genome-wide mutation load and its correlation with the outcome of peginterferon-alpha2a and ribavirin combination therapy. PLoS One 9:e100131
Wang, Weihua; Zhang, Xiaoan; Xu, Yanjuan et al. (2013) Viral categorization and discovery in human circulation by transcriptome sequencing. Biochem Biophys Res Commun 436:525-9
Lu, Yang; Xu, Yanjuan; Di Bisceglie, Adrian M et al. (2013) Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus. J Virol Methods 191:105-12
Zhang, Xiaoan; Ryu, Soo Hyung; Xu, Yanjuan et al. (2011) The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. J Clin Virol 52:333-8
Wang, Weihua; Lin, Jianguo; Tan, De et al. (2011) Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Biochem Biophys Res Commun 414:148-52
Pickett, B E; Striker, R; Lefkowitz, E J (2011) Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 18:608-18
Zhang, Xiaoan; Fan, Xiaofeng; Xu, Yanjuan et al. (2010) Enhanced protocol for determining the 3' terminus of hepatitis C virus. J Virol Methods 167:158-64

Showing the most recent 10 out of 12 publications